...
首页> 外文期刊>Bone marrow transplantation >Isolation and transplantation of highly purified autologous peripheral CD34(+) progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma.
【24h】

Isolation and transplantation of highly purified autologous peripheral CD34(+) progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma.

机译:高纯度神经母细胞瘤患儿的高纯度自体外周血CD34(+)祖细胞的分离和移植:清除功效,造血重建和长期预后。

获取原文
获取原文并翻译 | 示例
           

摘要

We have investigated the purging efficacy of positive selection of autologous mobilized CD34(+) peripheral stem cells in 22 children with high-risk neuroblastoma. CD34(+) cell selection was performed using the method of magnetic-activated cell sorting (MACS). The median purity of the CD34(+) cells post selection was 97.6% (range 81.7-99.7). For detection of contaminating neuroblastoma cells before and after CD34(+) selection, the chimeric anti-disialoganglioside GD2 antibody delta ch 14.18 was used. Prior to positive selection, various numbers of contaminating neuroblastoma cells were found in 17 patients. After positive CD34(+) cell selection, low numbers of neuroblastoma cells were only detectable in four patients. In 18 patients, high-dose chemotherapy was performed and the isolated CD34(+) cells were reinfused. In all patients, a rapid neutrophil recovery was seen with a median time to reach 0.5 x 10(9)/l neutrophils of 12 days (range 8-24 days). Nine of the 18 patients are free of progression with a median follow-up of 55 months (range 45-70 months). Two patients are alive with relapse, six patients died due to progression or relapse and one patient died due to secondary AML 10 months after transplant while in remission from neuroblastoma. In summary, we show that, through a highly effective positive selection method, a high purging efficacy can be obtained without compromising the hematopoietic reconstitution capacity of the graft.
机译:我们调查了积极选择自体动员的CD34(+)外周血干细胞在22例高危神经母细胞瘤患儿中的清除效果。使用磁激活细胞分选(MACS)的方法进行CD34(+)细胞选择。选择后CD34(+)细胞的中位纯度为97.6%(范围81.7-99.7)。为了在选择CD34(+)之前和之后检测污染的神经母细胞瘤细胞,使用了嵌合的抗二唾液酸神经节苷脂GD2抗体δch 14.18。在阳性选择之前,在17位患者中发现了多种污染性神经母细胞瘤细胞。在选择阳性CD34(+)细胞后,仅在四名患者中检测到少量神经母细胞瘤细胞。在18例患者中,进行了大剂量化疗并重新注入了分离的CD34(+)细胞。在所有患者中,均观察到中性粒细胞快速恢复,中位时间达到0.5天的12天(8-24天)达到0.5 x 10(9)/ l中性粒细胞。 18名患者中有9名没有进展,中位随访时间为55个月(范围45-70个月)。存活10例,其中2例复发,6例因进展或复发而死亡,1例因成神经细胞瘤缓解而在移植后10个月死于继发性AML。总而言之,我们表明,通过一种高效的阳性选择方法,可以在不损害移植物的造血重建能力的情况下获得高净化效果。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号